RCD Chooses Cannabis Science, Inc.'s www.iCannabinoid.com to Interact and Inform on All Company Projects, Drug Development, and All RCD Initiatives
January 23, 2019 at 02:38 pm
Cannabis Science, Inc. announced that beginning RCD will use the www.iCannabinoid.com online information sharing platform to interact with the general public on all Company projects, Drug Development initiatives, Partnership programs, CBIS Consortium, University Scholarship programs, and all RCD initiatives. Cannabis Science’s primary objective is to research and develop U.S. Food and Drug Administration (FDA)-approved, cannabinoid-based medicine to fight a number of targeted critical ailments, including various Cancers, Neurological Conditions, PTSD, Sleep Deprivation, Chronic Pain, HIV/AIDS, Autism, Parkinson’s Disease, Epilepsy, Chronic Obstructive Pulmonary Disease (COPD), and others. CBIS and its collaborators are well underway on a number of research projects targeting Lung Cancer, Pancreatic Cancer, Neurological conditions including PTSD, Chronic Pelvic Pain, and Oro-bucco-lingual Dyskinesias, to name a few.